202 related articles for article (PubMed ID: 25534733)
1. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.
Shields RK; Nguyen MH; Potoski BA; Press EG; Chen L; Kreiswirth BN; Clarke LG; Eschenauer GA; Clancy CJ
Antimicrob Agents Chemother; 2015 Mar; 59(3):1797-801. PubMed ID: 25534733
[TBL] [Abstract][Full Text] [Related]
2. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.
Clancy CJ; Chen L; Hong JH; Cheng S; Hao B; Shields RK; Farrell AN; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2013 Nov; 57(11):5258-65. PubMed ID: 23939888
[TBL] [Abstract][Full Text] [Related]
3. Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.
Hong JH; Clancy CJ; Cheng S; Shields RK; Chen L; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2013 May; 57(5):2147-53. PubMed ID: 23459476
[TBL] [Abstract][Full Text] [Related]
4. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.
Clancy CJ; Hao B; Shields RK; Chen L; Perlin DS; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2014 Jun; 58(6):3521-5. PubMed ID: 24566172
[TBL] [Abstract][Full Text] [Related]
5. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
6. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae.
Landman D; Bratu S; Quale J
J Med Microbiol; 2009 Oct; 58(Pt 10):1303-1308. PubMed ID: 19556371
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen.
Oliva A; Mascellino MT; Cipolla A; D'Abramo A; De Rosa A; Savinelli S; Ciardi MR; Mastroianni CM; Vullo V
Int J Infect Dis; 2015 Apr; 33():132-4. PubMed ID: 25597275
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Genetic Background of KPC-2-Producing
Wu LT; Guo MK; Ke SC; Lin YP; Pang YC; Nguyen HV; Chen CM
Microb Drug Resist; 2020 Sep; 26(9):1050-1057. PubMed ID: 32283046
[TBL] [Abstract][Full Text] [Related]
9. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India.
Kaur A; Gandra S; Gupta P; Mehta Y; Laxminarayan R; Sengupta S
Am J Infect Control; 2017 Nov; 45(11):1289-1291. PubMed ID: 28807425
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Qureshi ZA; Paterson DL; Potoski BA; Kilayko MC; Sandovsky G; Sordillo E; Polsky B; Adams-Haduch JM; Doi Y
Antimicrob Agents Chemother; 2012 Apr; 56(4):2108-13. PubMed ID: 22252816
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of high-level carbapenem resistance in Klebsiella pneumoniae: underlying Ompk36-deficient strains represent a threat of emerging high-level carbapenem-resistant K. pneumoniae with IMP-1 β-lactamase production in Japan.
Sho T; Muratani T; Hamasuna R; Yakushiji H; Fujimoto N; Matsumoto T
Microb Drug Resist; 2013 Aug; 19(4):274-81. PubMed ID: 23514607
[TBL] [Abstract][Full Text] [Related]
13. An Update of the Evolving Epidemic of blaKPC Carrying Klebsiella pneumoniae in Sicily, Italy, 2014: Emergence of Multiple Non-ST258 Clones.
Bonura C; Giuffrè M; Aleo A; Fasciana T; Di Bernardo F; Stampone T; Giammanco A; ; Palma DM; Mammina C
PLoS One; 2015; 10(7):e0132936. PubMed ID: 26177547
[TBL] [Abstract][Full Text] [Related]
14. Reduced Susceptibility to Carbapenems in a Klebsiella pneumoniae Clinical Isolate Producing SCO-1 and CTX-M-15 β-Lactamases Together with OmpK35 and OmpK36 Porin Deficiency.
Venditti C; Butera O; Proia A; Rigacci L; Mariani B; Parisi G; Messina F; Capone A; Nisii C; Di Caro A
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423955
[No Abstract] [Full Text] [Related]
15. Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
Jacobs DM; Safir MC; Huang D; Minhaj F; Parker A; Rao GG
Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):76. PubMed ID: 29178957
[TBL] [Abstract][Full Text] [Related]
16. Global survey of Klebsiella pneumoniae major porins from ertapenem non-susceptible isolates lacking carbapenemases.
Wise MG; Horvath E; Young K; Sahm DF; Kazmierczak KM
J Med Microbiol; 2018 Mar; 67(3):289-295. PubMed ID: 29458684
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit.
Sbrana F; Malacarne P; Viaggi B; Costanzo S; Leonetti P; Leonildi A; Casini B; Tascini C; Menichetti F
Clin Infect Dis; 2013 Mar; 56(5):697-700. PubMed ID: 23155147
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients.
Clancy CJ; Chen L; Shields RK; Zhao Y; Cheng S; Chavda KD; Hao B; Hong JH; Doi Y; Kwak EJ; Silveira FP; Abdel-Massih R; Bogdanovich T; Humar A; Perlin DS; Kreiswirth BN; Hong Nguyen M
Am J Transplant; 2013 Oct; 13(10):2619-33. PubMed ID: 24011185
[TBL] [Abstract][Full Text] [Related]
19. First Detection of Colistin-Resistant
Nawfal Dagher T; Azar E; Al-Bayssari C; Chamieh AS; Rolain JM
Microb Drug Resist; 2019; 25(6):925-930. PubMed ID: 30883263
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
Hagihara M; Crandon JL; Urban C; Nicolau DP
J Antimicrob Chemother; 2013 Jul; 68(7):1616-8. PubMed ID: 23475648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
